Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 4 years of Other Operating Expenses data on record, last reported at -$373354.0 in Q1 2026.

  • On a quarterly basis, Other Operating Expenses rose 67.95% to -$373354.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$582432.0, a 50.0% increase, with the full-year FY2025 number at -$1.4 million, changed N/A from a year prior.
  • Other Operating Expenses reached -$373354.0 in Q1 2026 per IKT's latest filing, down from $642169.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for IKT hit a ceiling of $642169.0 in Q4 2025 and a floor of -$10.6 million in Q4 2023.
  • A 3-year average of -$2.1 million and a median of -$433090.5 in 2025 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 67.95% in 2026 and fell as far as 67.95% in 2026.
  • Tracing IKT's Other Operating Expenses over 3 years: stood at -$10.6 million in 2023, then surged by 106.07% to $642169.0 in 2025, then tumbled by 158.14% to -$373354.0 in 2026.
  • Business Quant data shows Other Operating Expenses for IKT at -$373354.0 in Q1 2026, $642169.0 in Q4 2025, and -$492827.0 in Q3 2025.